Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $142,017.12 in Stock

Key Points

• Director Kenneth Cunningham of Verona Pharma PLC sold 10,808 shares of the company's stock for a total of $142,017.12, which marked an 11.93% decrease in his position.
• The stock's current trading price is $105.40, with a market capitalization of $8.97 billion and a P/E ratio of -52.70.
• Analysts have downgraded Verona Pharma to a "hold" rating, with the average target price set at $109.00 following recent assessments by various research firms.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) Director Kenneth Cunningham sold 10,808 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $142,017.12. Following the completion of the transaction, the director owned 79,776 shares in the company, valued at $1,048,256.64. The trade was a 11.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Verona Pharma PLC American Depositary Share Stock Down 0.1%

Shares of NASDAQ:VRNA traded down $0.07 during midday trading on Tuesday, reaching $105.40. The company had a trading volume of 861,362 shares, compared to its average volume of 8,219,019. The company has a debt-to-equity ratio of 1.07, a current ratio of 8.86 and a quick ratio of 8.73. The stock's fifty day moving average price is $94.93 and its 200-day moving average price is $74.38. The stock has a market capitalization of $8.97 billion, a P/E ratio of -52.70 and a beta of 0.12. Verona Pharma PLC American Depositary Share has a one year low of $19.45 and a one year high of $105.50.

Analyst Ratings Changes

Several research firms recently commented on VRNA. BTIG Research lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Roth Capital lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. HC Wainwright reiterated a "neutral" rating and set a $107.00 price objective (up previously from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, July 14th. Wells Fargo & Company lowered shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and dropped their price objective for the company from $138.00 to $107.00 in a research note on Thursday, July 10th. Finally, Cowen lowered shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Eleven research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, Verona Pharma PLC American Depositary Share has an average rating of "Hold" and an average target price of $109.00.

Institutional Trading of Verona Pharma PLC American Depositary Share

Hedge funds and other institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. bought a new stake in shares of Verona Pharma PLC American Depositary Share in the first quarter worth $34,000. IFP Advisors Inc acquired a new position in Verona Pharma PLC American Depositary Share in the second quarter worth $52,000. Geneos Wealth Management Inc. boosted its holdings in Verona Pharma PLC American Depositary Share by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock worth $40,000 after purchasing an additional 193 shares during the period. Acadian Asset Management LLC acquired a new position in Verona Pharma PLC American Depositary Share in the first quarter worth $48,000. Finally, NewEdge Advisors LLC acquired a new position in Verona Pharma PLC American Depositary Share in the first quarter worth $58,000. Institutional investors own 85.88% of the company's stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.